Location of colorectal cancer impacts survival chances

This article originally appeared here.
Location of Colorectal Cancer Factors Into Survival
Location of Colorectal Cancer Factors Into Survival

(HealthDay News) -- Patients with metastatic colorectal cancer that started on the left side may be more likely to survive than those whose disease originated on the right side, according to research published in the March issue of the Journal of the National Cancer Institute.

A team led by Fotios Loupakis, M.D., Ph.D., of the University of Southern California Norris Comprehensive Cancer Center in Los Angeles, tracked data from three studies that included 2,027 metastatic colorectal cancer patients.

The 70 percent of patients whose cancer began in the left side had a better survival rate than those whose primary cancer was on the right side, the researchers found. Analysis of another study of 200 metastatic colorectal cancer patients yielded similar findings.

The results suggest that tumor location "could be of added value in clinical decision-making, and should be considered an important stratification factor for future randomized trials," the team concluded. Writing in an accompanying journal editorial, Howard Hochster, M.D., of the Yale School of Medicine in New Haven, Conn., said the findings are from patients with metastatic colorectal cancer and may not apply to those who have had surgery to remove primary tumors.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs